Background To overcome the several drawbacks of warfarin, non-vitamin K antagonist oral
anticoagulants (NOACs) were developed. Even though randomized controlled trials (RCTs) …

Background: Non-vitamin K antagonist oral anticoagulants (NOAC) have been developed as
alternatives to warfarin. Until recently, the latter was the standard oral anticoagulant for …

The non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly
prescribed in clinical practice for stroke prevention in patients with nonvalvular atrial …

Clinical guidelines for the prevention of stroke in patients with nonvalvular atrial fibrillation
(NVAF) are available from several international cardiology associations. Patients with NVAF …

Background and Purpose—The use of vitamin K antagonists (VKAs), the cornerstone
treatment for stroke prevention in patients with atrial fibrillation, is limited by the perceived …

Background The global real-life impact of non-vitamin K antagonist oral anticoagulants
(NOACs) introduction in the healthcare system in a setting of well-managed vitamin K …

We aimed to compare effectiveness and safety of the non‐vitamin K antagonist oral
anticoagulants (NOACs) vs. warfarin for stroke prevention in nonvalvular atrial fibrillation …

Background and Purpose—Several randomized trials and real-world studies have reported
the efficacy and safety of non–vitamin K antagonist oral anticoagulants (NOACs) in Asian …

Background This meta-analysis aimed to evaluate the efficacy and safety of non-vitamin K
antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in secondary …

Atrial fibrillation is a heart arrhythmia associated with increased risk for ischemic stroke.
Vitamin K antagonists were developed to decrease a patient's clotting risk; however, these …